Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.65 |
| ▸ | NPC1 | O15118 | 13/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 5/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL14719213 | 0.87 | PTGS1 (0.57) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL30366944 | 0.87 | RAB9A (0.69) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL13325909 | 0.87 | RAB9A (0.83) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL14076569 | 0.85 | KDM4E (0.72) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL13325938 | 0.85 | RAB9A (0.80) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL5776801 | 0.84 | RAB9A (0.65) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL6388717 | 0.82 | RAB9A (0.71) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL13325735 | 0.82 | RAB9A (0.75) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL4728174 | 0.81 | KDM4E (0.75) | RAB9ANPC1KDM4EPOLBPKM | |
| SCHEMBL1494782 | 0.81 | KDM4E (0.75) | RAB9ANPC1KDM4EPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| EP-2491009-B1 | CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-20130053412-A1 | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | disclosed |
| WO-2011048018-A1 | CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | RAB9A 2204/4885NPC1 356/4885KDM4E 3693/4885 |
| US-20130053412-A1 | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use | CPT1A, FASN, CES1 | RAB9A 4531/4885NPC1 116/4885KDM4E 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.